We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Institute of Biomedical Research Corporation New (PK) | USOTC:MRES | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00025 | 3.27% | 0.0079 | 0.0065 | 0.009 | 0.0091 | 0.00685 | 0.007 | 893,154 | 21:03:40 |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 12b-25
NOTIFICATION OF LATE
FILING
|
OMB
APPROVAL
|
|
OMB
Number: 3235-0058
|
||
Expires: May 31,
2012
|
||
Estimated average burden hours per
response ... 2.50
|
||
SEC FILE
NUMBER
|
||
33-55254-42
|
||
CUSIP
NUMBER
|
||
(Check
one):
|
o
Form 10-K
o
Form 20-F
o
Form 11-K
x
Form 10-Q
o
Form 10-D
o
Form N-SAR
o
Form N-CSR
|
||
For Period
Ended:
|
June 30,
2010
|
||
o
Transition Report on
Form 10-K
|
|||
o
Transition Report on
Form 20-F
|
|||
o
Transition Report on
Form 11-K
|
|||
o
Transition Report on
Form 10-Q
|
|||
o
Transition Report on
Form N-SAR
|
|||
For the Transition Period
Ended:
|
Read Instruction (on back page)
Before Preparing Form. Please Print or Type.
Nothing in this form shall be
construed to imply that the Commission has verified any information
contained herein.
|
x
|
(a)
|
The reasons described in
reasonable detail in Part III of this form could not be eliminated without
unreasonable effort or
expense;
|
x
|
(b)
|
The subject annual report,
semi-annual report, transition report on Form 10-K, Form 20-F,11-K or Form
N-SAR, or portion thereof, will be filed on or before the fifteenth
calendar day following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or portion thereof will be filed
on or before the fifth calendar day following the prescribed due date;
and
|
o
|
(c)
|
The accountant's statement or
other exhibit required by Rule 12b-25(c) has been attached if
applicable.
|
SEC 1344
(03-05)
|
Persons who are to respond to the
collection of information contained in this form are not required to
respond unless the form displays a currently valid OMB control
number.
|
(1)
|
Name and telephone number of
person to contact in regard to this notification
|
|||||
Barry
Somervail
|
41
|
61
500 05 16
|
||||
(Name)
|
(Area Code)
|
(Telephone
Number)
|
||||
(2)
|
Have all other periodic reports
required under Section 13 or 15(d) of the Securities Exchange Act of
1934 or Section 30 of the Investment Company Act of 1940 during the
preceding 12 months or for such shorter period that the registrant
was required to file such report(s) been filed? If answer is no, identify
report(s).
|
|
Yes
x
No
o
|
||
(3)
|
Is it anticipated that any
significant change in results of operations from the corresponding period
for the last fiscal year will be reflected by the earnings statements to
be included in the subject report or portion
thereof?
|
|
Yes
o
No
x
|
||
If so, attach an explanation of
the anticipated change, both narratively and quantitatively, and, if
appropriate, state the reasons why a reasonable estimate of the results
cannot be made.
|
||
Date:
|
August 16,
2010
|
By:
|
/s/ Barry
Somervail
|
|||
Barry
Somervail
|
||||||
Chief
Executive Officer
|
||||||
1 Year Institute of Biomedical ... (PK) Chart |
1 Month Institute of Biomedical ... (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions